(A) Nuclear extracts of the CTCL cell lines HUT78, MyLa, and SeAx contain myc-oligo binding activities, which include c-Myc and Max. Lane 1, peripheral blood lymphocytes; lanes 2 through 4, HUT78 nuclear extracts; lanes 5 through 7, MyLa nuclear extracts; lanes 8 through 10, SeAx nuclear extracts. Lanes 3, 6, and 9, coincubation with Max antibody; lanes 4, 7, and 10, coincubation with c-Myc antibody. (B) Myc-oligo binding activities in the nuclear extracts of malignant cells of seven SS patients (lanes 3 to 9). Lane 1, peripheral blood lymphocytes (negative control); lane 2, nuclear extract from HUT78 cells (positive control). (C) The myc-oligo–binding activities of patient 2 contain c-Myc and Max. Lane 1, peripheral blood lymphocytes (negative control); lane 2, nuclear extract without antibody; lane 3, nuclear extract with Max antibody; lane 4, nuclear extract with c-Myc antibody; lane 5, competition experiment with a 100-fold excess of unlabeled myc-oligo in the absence of antibodies. The position of the complexes C1-C4 and the DNA-c-Myc/Max-antibody complexes (AbC) are indicated on the right.